23/05/2025 – AB Science today announces the settlement and delivery of its capital increase announced on May 20, 2025 for an amount of €1.8 million, subscribed by a limited number of investors Download PDF Post navigationPreviousPrevious post:AB Science announces the successful completion of a EUR 1.8 million private placementNextNext post:AB Science announces EMA approval of Masivet shelf-life extension to 4 yearsRelated PostsAB Science patent for masitinib in the treatment of sickle cell disease formally granted in the US with a protection until 2040December 22, 2025AB Science announces the initiation of coverage of its stock by Maxim Group with a target price of EUR 4.0 per shareDecember 18, 2025AB Science announces a new publication on biorxiv that identifies AB8939 as a promising drug candidate for treating refractory acute myeloid leukemia and potentially other cancersDecember 15, 2025AB Science announces new publication on Medrxiv highlighting clinical benefit with masitinib in Amyotrophic Lateral Sclerosis patients prior any complete loss of functionDecember 11, 2025AB Science announces the successful completion of a 2.8 million euros private placementOctober 17, 2025Summary of the virtual conference held on October 16, 2025October 16, 2025
AB Science patent for masitinib in the treatment of sickle cell disease formally granted in the US with a protection until 2040December 22, 2025
AB Science announces the initiation of coverage of its stock by Maxim Group with a target price of EUR 4.0 per shareDecember 18, 2025
AB Science announces a new publication on biorxiv that identifies AB8939 as a promising drug candidate for treating refractory acute myeloid leukemia and potentially other cancersDecember 15, 2025
AB Science announces new publication on Medrxiv highlighting clinical benefit with masitinib in Amyotrophic Lateral Sclerosis patients prior any complete loss of functionDecember 11, 2025
AB Science announces the successful completion of a 2.8 million euros private placementOctober 17, 2025
